NASDAQ:GRTX Galera Therapeutics (GRTX) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free GRTX Stock Alerts $0.21 +0.02 (+10.67%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.18▼$0.2150-Day Range$0.14▼$0.2752-Week Range$0.09▼$3.59Volume662,154 shsAverage Volume2.35 million shsMarket Capitalization$11.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Galera Therapeutics alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Galera Therapeutics Stock (NASDAQ:GRTX)Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Read More GRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRTX Stock News HeadlinesApril 16, 2024 | americanbankingnews.comGalera Therapeutics (NASDAQ:GRTX) Trading Down 3.8%April 1, 2024 | msn.comGalera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory ChallengesApril 25, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 28, 2024 | finanznachrichten.deGalera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesMarch 28, 2024 | globenewswire.comGalera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesMarch 16, 2024 | finance.yahoo.comGRTX Apr 2024 0.500 callMarch 12, 2024 | nz.finance.yahoo.comGalera Therapeutics, Inc. (GRTX)February 27, 2024 | edition.cnn.comGalera Therapeutics, Inc.April 25, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…February 4, 2024 | investing.comGalera Therapeutics Inc (GRTX)February 4, 2024 | benzinga.comGalera Therapeutics Stock (NASDAQ:GRTX) Dividends: History, Yield and DatesJanuary 21, 2024 | finance.yahoo.comGalera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17January 16, 2024 | bizjournals.comLocal publicly traded stocks lag far behind national indices in 2023January 9, 2024 | msn.comDow Tumbles Over 200 Points; US Trade Gap Narrows In NovemberNovember 28, 2023 | msn.comGalera Therapeutics (GRTX) Price Target Increased by 7.14% to 0.38November 14, 2023 | finanznachrichten.deGalera Therapeutics: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 14, 2023 | benzinga.comGalera Therapeutics: Q3 Earnings InsightsNovember 14, 2023 | finance.yahoo.comGalera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 13, 2023 | benzinga.comGalera Therapeutics's Earnings OutlookNovember 1, 2023 | benzinga.comUS Stocks Fall; Pfizer Swings To Q3 LossOctober 31, 2023 | benzinga.comDow Gains 50 Points; Global Payments Posts Upbeat EarningsOctober 31, 2023 | bizjournals.comGalera Therapeutics warns of potential shutdown as it halts clinical trials and stock tanksOctober 31, 2023 | msn.comWhy Is Cancer Focused Galera Therapeutics Stock Sinking Today?October 31, 2023 | msn.comGalera plunges after citing risks to business continuityOctober 31, 2023 | finanznachrichten.deGalera Therapeutics: Galera Announces Receipt of Type A Meeting Minutes and Strategic UpdateOctober 31, 2023 | finance.yahoo.comGalera Announces Receipt of Type A Meeting Minutes and Strategic UpdateSeptember 19, 2023 | markets.businessinsider.comGalera Therapeutics (GRTX) Gets a Hold from H.C. WainwrightSee More Headlines Receive GRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GRTX CUSIPN/A CIK1563577 Webwww.galeratx.com Phone610-725-1500FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,080,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-137.47% Debt Debt-to-Equity RatioN/A Current Ratio4.36 Quick Ratio4.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.41) per share Price / Book-0.09Miscellaneous Outstanding Shares54,392,000Free Float50,639,000Market Cap$11.29 million OptionableOptionable Beta2.17 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. J. Mel Sorensen M.D. (Age 67)CEO, President & Director Comp: $632.64kDr. Robert A. Beardsley M.B.A. (Age 62)Ph.D., Co-Founder & COO Comp: $464.59kMr. Christopher Degnan (Age 44)Chief Financial Officer Comp: $474.05kMs. Jennifer Evans Stacey Esq. (Age 59)Chief Legal & Compliance Officer and Secretary Ms. Andie CollierChief Regulatory & Quality Affairs OfficerMs. Judy SchnyderSenior Vice President of Clinical Operations & Data ManagementMore ExecutivesKey CompetitorsEterna TherapeuticsNASDAQ:ERNAElevai LabsNASDAQ:ELABGuardion Health SciencesNASDAQ:GHSIMoleculin BiotechNASDAQ:MBRXAlterity TherapeuticsNASDAQ:ATHEView All CompetitorsInstitutional Ownershipabrdn plcBought 898,374 shares on 1/31/2024Ownership: 1.652%View All Institutional Transactions GRTX Stock Analysis - Frequently Asked Questions Should I buy or sell Galera Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" GRTX shares. View GRTX analyst ratings or view top-rated stocks. How have GRTX shares performed in 2024? Galera Therapeutics' stock was trading at $0.1454 at the beginning of the year. Since then, GRTX shares have increased by 42.7% and is now trading at $0.2075. View the best growth stocks for 2024 here. Are investors shorting Galera Therapeutics? Galera Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 2,660,000 shares, an increase of 50.3% from the March 31st total of 1,770,000 shares. Based on an average trading volume of 1,950,000 shares, the short-interest ratio is presently 1.4 days. Approximately 6.5% of the company's stock are short sold. View Galera Therapeutics' Short Interest. When is Galera Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GRTX earnings forecast. How were Galera Therapeutics' earnings last quarter? Galera Therapeutics, Inc. (NASDAQ:GRTX) issued its quarterly earnings results on Thursday, March, 28th. The company reported ($0.10) earnings per share for the quarter. What other stocks do shareholders of Galera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), Ardelyx (ARDX), Chiasma (CHMA), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV). When did Galera Therapeutics IPO? Galera Therapeutics (GRTX) raised $75 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse acted as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Galera Therapeutics? Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
